Her family feared Cystic Fibrosis would rob her of a childhood.
She swims freestyle in the medley relay.
That is what drives us. Experience, Rho.
In recent times, the prevalence of respiratory diseases has dramatically increased due to a combination of lifestyle choices and environmental pollutants. Worldwide, asthma affects more than 300 million people, and lung conditions such as COPD kill more than 3 million people every year. The symptoms of these conditions can have significant impacts on the quality of life for patients and their caregivers, affecting them physically and mentally.
Clinical trials in the respiratory therapeutic area present a multitude of challenges and require the clinical expertise of a seasoned, global CRO. And when it comes to respiratory diseases such as asthma, cystic fibrosis and COPD, the nuances and additional technical knowledge required for the handling of various instruments for disease management can make executing successful respiratory clinical trials seem like a daunting task.
Our global client solutions will ensure you reach your patients, wherever they are. With international capabilities that span 5 continents, we provide full-service capabilities to execute your clinical development programs and trials across the globe.
Why Choose Rho?
Committed to Respiratory Research
Rho has a deep and long-standing commitment to research in respiratory diseases, having supported groundbreaking research in inner-city asthma and peanut allergies beginning in 1997. Drawing on this dedication and exceptional experience, our project teams understand what it takes to successfully enroll and execute respiratory studies.
With any respiratory program, building and maintaining strong relationships is critical. For this reason, we make a concerted effort to keep our cross-functional respiratory teams together over the course of multiple studies—aiding development of our therapeutic indication expertise.
Along with conducting inpatient and outpatient studies, we have experience coordinating standard of care with study-specific procedures and assessments, as well as interacting with multidisciplinary care teams. Through our extensive expertise, we have developed strong relationships with high-performing and high-enrolling sites equipped with trained investigators and staff – allowing us to consistently meet or exceed our sponsors’ start-up timelines.
Our cross-functional, collaborative approach allows us to identify challenges earlier, de-risk your development strategy, and eliminate the missteps and delays often caused by silos and handoffs – ultimately ensuring a consistent program that runs smarter and more efficiently.
Rho not only gave Anthera a clear picture of how their team would fulfill the study needs, but showed their knowledge and expertise of the [Cystic Fibrosis] indication as well as the protocol in a way that made them a collaborative partner rather than a service provider.
Monica Gangal – Former VP of Clinical Operations at Anthera
Expertise in Action
Rho has developed relationships with 40+ cystic fibrosis research centers in North America and Europe (both CFF TDNCC and ECFS CTN sites, as well as non-CFF TDN and non-ECFS CTN sites) and has led 10 cystic fibrosis studies and 2 marketing application submission efforts in just the past 3 years.
Rho’s experts have experience with CF gene therapy studies, as well aerosolized products, oral therapies, and inpatient, PK, PERT/GI, and anti-infective studies. Additionally, Rho has expertise with common CF assessments and endpoints, including CFA, CFQ-R, CNA, FEV1/FVC, MCC, and sputum collection.
Following study start-up for a Phase III cystic fibrosis study, the Cystic Fibrosis Foundation Therapeutics Development Network (CFF TDNCC) conducted a survey of participating clinical sites to assess their satisfaction with Rho. Some highlights include:
- 100% of sites ranked Rho as good or excellent for 6 of the 7 questions asked. For the seventh question, 90% of sites ranked Rho as good or excellent.
- On all questions, Rho scored higher than the CFF TDNCC average.
- “Rho is tremendous! Their people put in the extra effort to get our site initiated over a weekend in order to make it easier for a subject.”
Rho has supported more than 50 asthma trials over the past 3 decades and we offer full-service clinical trial solutions for adult and pediatric populations. We have proven metrics demonstrating study start-up and enrollment timelines that consistently exceed projections for our sponsors.
- 50+ clinical studies
- 700+ sites
- 65K+ patients
As a measure of the value of Rho’s contributions to allergy and asthma research, Rho allergy and asthma staff have co-authored over 80 manuscripts, including several in high-impact journals, such as the New England Journal of Medicine, Nature Immunology, and Science Translational Medicine.
Ihab Abdel-Fattah, M.D., Ph.D.
Senior Medical Director
Jamie Chang, M.D.
Senior Medical Director
Cindy Visness, Ph.D.
Principal Research Scientist
Caitlin Hirschman, R.N.
Principal Clinical Team Lead
Senior Clinical Team Lead
Egle Garbuziene, M.D.
Senior Clinical Team Lead
Senior Director, Biostatistics Strategy
Senior Project Manager
Ramona Kruce, Ph.D.
Case Study: Rho and Anthera Pharmaceuticals’ Collaborative Partnership in Cystic Fibrosis
In this case study, Rho and Anthera Pharmaceuticals collaborated in developing a product to treat Cystic Fibrosis. Read more about this partnership.
Clinical Project Management
Clinical Monitoring & Operations
Risk-Based Quality Management
Clinical Data Management
Randomization & Trial Supply Management